Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma

Area of Science:

• Neuro-oncology
• Molecular diagnostics
• Targeted therapy

Background:

• Pleomorphic xanthoastrocytoma (PXA) is a rare primary brain tumor.
• The anaplastic variant of PXA carries a poorer prognosis.
• PXA frequently harbors the BRAF V600E mutation, making it a candidate for targeted therapies.

Observation:

• A case of disseminated anaplastic pleomorphic xanthoastrocytoma relapse in an adolescent patient after standard treatments (surgery, radiotherapy, chemotherapy).

Findings:

• The patient experienced a significant and sustained response to Dabrafenib (a BRAF inhibitor).
• Upon tumor progression, the addition of Trametinib (a MEK inhibitor) further improved the response.
• The patient remained alive for over two years with good quality of life and minimal side effects.

Implications:

• Targeted therapy, specifically BRAF and MEK inhibition, shows promise for managing aggressive, BRAF-mutated brain tumors.
• This case underscores the efficacy of precision medicine in treating rare and high-grade brain malignancies.
• Further investigation into targeted treatments for BRAF-mutated central nervous system tumors is warranted.